The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial

This report has been verified by one or more authors of the original publication.

73 patients were randomized to determine the effect of a bisphosphonate therapy on bone mineral density (BMD) of the periprosthetic regions following total hip arthroplasty (THA). Patients received either risedronate or a placebo once a week for 6 months, and were followed-up for 24 months postoperatively. Results indicated that bone resorption in the periprosthetic regions was reduced with risedronate for up to a year, and that clinical, radiographic, and adverse-event outcomes were unaffected.